2021 American Transplant Congress
Mapping Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) in Kidney Transplant Biopsies Reveals Two Classes of Early AKI That Differ in Their Response-to-Wounding
*Purpose: We recently analyzed injury-induced molecular changes in kidney transplant biopsies using principal component analysis (PCA) (AJT https://doi.org/10.1111/ajt.16374). PC1 reflected all injury, PC2 distinguished early…2021 American Transplant Congress
High Levels of Donor-Derived Cell-Free DNA Predict EGFR Decline After Kidney Transplantation
*Purpose: Persistent, low-grade inflammation is associated with decline in eGFR. Cross-sectional studies have demonstrated a consistent association between circulating inflammatory markers and kidney function. Our…2021 American Transplant Congress
Immunosuppression Reduction Strategies for Polyoma BK Viremia in Kidney Transplant Patients on Belatacept-Based Immunosuppression
*Purpose: The mainstay of treatment for BK infection is immunosuppression (IS) reduction, however limited literature provides guidance for treatment of patients with a belatacept-based IS…2021 American Transplant Congress
Single Cell Rna-Sequencing of Urinary Cells and Defining the Immune Landscape of Rejection in Human Kidney Allografts
*Purpose: Transcriptome-based clustering of urinary cells in kidney transplant recipients may help identify cell-type specific injury and develop cell-type specific biomarkers for the noninvasive assessment…2021 American Transplant Congress
Successful Long-Term TMA- and Rejection-Free Survival of a Kidney Xenograft With Triple Xenoantigen Knockout Plus Insertion of Multiple Human Transgenes
*Purpose: Pigs with deletion of 3 carbohydrate xenoantigens (triple knock-out, TKO) are expected to be optimal donors for human xenotransplantation. However, anti-porcine natural antibodies of…2021 American Transplant Congress
Athena – Effect of Primary Immunosuppression on Development of De Novo Donor Specific Antibodies within First Year After Kidney Transplantation
1ATHENA, Study Group, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany
*Purpose: The ATHENA trial [NCT01843348] investigated safety and efficacy of everolimus combined with cyclosporine A [EVR/CsA] or tacrolimus [EVR/TAC] vs. tacrolimus plus mycophenolic acid [MPA/TAC]…2021 American Transplant Congress
Association Between Donor-Recipient Genetic Matching and Acute Rejection in Kidney Transplantation
*Purpose: In this study we carried out a genome-wide association study (GWAS) between donor-recipient matching scores at individual SNP level and Acute rejection (AR) in…2021 American Transplant Congress
Sampling Renal Biopsies in Pre-Clinical Research for Comprehensive Assessment
*Purpose: Previous literature has demonstrated that single biopsies are not representative of a whole kidney in clinical assessments. In this study we aimed to design…2021 American Transplant Congress
Initial Experience with TrugrafTm Gene Expression Profile and TracTm Dd-cfdna Testing in Kidney Transplant Recipients Suggests Synergy and Enhanced Management within the First Year Post-transplant and Beyond
Nephrology, Baystate Medical Center, Springfield, MA
*Purpose: Non-invasive validated rejection biomarkers are now available to monitor kidney transplant patients (KTRs). Two such biomarkers are; TruGrafTM (TG) gene expression profile validated to…2021 American Transplant Congress
Torque Teno Virus Load Predicts Allograft Rejection but Not Viral Infection After Kidney Transplantation; A Cohort Joint Modelling Study
*Purpose: The main challenge of immunosuppressive therapy after solid organ transplantation is to find the optimal dose regimen, and prevent allograft rejection as well as…
- « Previous Page
- 1
- …
- 106
- 107
- 108
- 109
- 110
- …
- 531
- Next Page »